Highlights include: a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center and a novel new partnership with Boundless Bio, a next-generation precision oncology company
CarePath, SOPHiA GENETICS’ next-generation solution based on up-to-date real-world observational data, was previewed to attendees
BOSTON and GENEVA, Switzerland, Sept. 21, 2022 (GLOBE NEWSWIRE) – SOPHiA GENETICS SOPHa cloud-native healthcare software company, held its first-ever Investor Day on Tuesday, September 20, 2022 in New York City.
The event, hosted by CEO and co-founder Dr. Jurgi Camblong and members of the executive team, provided a roadmap for the company’s long-term vision and highlighted new business opportunities and partnerships. One takeaway from the event was the entry of SOPHiA GENETICS into the biopharmaceutical space, opening the door to new opportunities for market growth. The audience also heard how the company’s strategic business model allows it to continue to offer solid depth in the clinical space.
“A key theme of the day was how we innovate; how, since its inception, SOPHiA GENETICS has identified opportunities in the healthcare industry to innovate and accelerate data sharing to advance medicine, research and patient care,” said Jurgi Camblong, CEO and co-founder, SOPHia GENETICS. “Our vision is made possible by the strong foundation on which our company has been built and the strategic relationships we have forged to advance our mission of democratizing data-driven medicine.”
New collaboration with one of the top cancer centers in the United States
SOPHiA GENETICS recently announced a letter of intent for a collaboration Memorial Sloan Kettering Cancer Center (“MSK”). Once the collaboration agreements are finalized, the power of SOPHiA GENETICS’ large, global network and deep expertise in predictive algorithms will be combined with MSK’s clinical expertise in cancer genomics….
